The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. This is a perpetual platform trial, which means there is a single Master Protocol that dictates the conduct of the trial. The Master Protocol describes the overall framework of the trial, including the target population, inclusion and exclusion criteria, regimen assignment and randomization schemes, the overall schedule of assessments, the study endpoints, trial design, the mechanisms for adding and removing interventions, and statistical methodology.